BN Business News
Add your company to Business Communicator →

BUSINESS NEWS

Search Business News

Find articles by title or summary.

3/20/2023

FAA Approves JFK Noise Compatibility Program

The Federal Aviation Administration (FAA) has approved the John F. Kennedy International Airport (JFK) noise compatibility program, which includes 15 approved measures, including seven noise abatement measures, after a final review process that began in 2022.

3/20/2023

Azoxystrobin; Pesticide Tolerances

The U.S. government has established pesticide tolerances for azoxystrobin residues on mango, papaya, and oil palm, following a request from Syngenta Crop Protection, LLC.

3/20/2023

EPA Extends Comment Period for Certain New Chemicals Under Review

The Environmental Protection Agency (EPA) has extended the public comment period for certain new chemicals under review until May 19, 2023, from the original March 20, 2023, deadline. The comment period was announced in the Federal Register on February 17, 2023, as part of the Toxic Substances Control Act (TSCA) review process.

3/20/2023

FDA Updates Regulations on Tobacco Products

The Food and Drug Administration (FDA) is updating its regulations to include products containing nicotine from any source, as mandated by the Consolidated Appropriations Act of 2022.

3/20/2023

FDA Updates Guidances on Tobacco Products

The Food and Drug Administration is updating its guidances on tobacco products in response to the Consolidated Appropriations Act of 2022, which expanded the definition of tobacco products to include nicotine-containing products from any source.

3/20/2023

Pharmacogenomic Data Submissions; Draft Guidance for Industry; Availability

The Food and Drug Administration (FDA) has released a draft guidance for industry on pharmacogenomic data submissions, aiming to facilitate progress in pharmacogenomics and its use in drug development. The guidance clarifies the contexts for including pharmacogenomic study findings and data in FDA submissions related to INDs, NDAs, and BLAs.

3/20/2023

FDA Determines Regulatory Review Period for JIVI Patent Extension Application

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for JIVI, a human biological product, following the submission of a patent extension application to the U.S. Patent and Trademark Office (USPTO). This determination is published as a notice, as required by law, and is related to the extension of JIVI's patent.